

HALOZYME THERAPEUTICS INC

Form 8-K

August 08, 2006

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
August 4, 2006
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)**

Nevada

000-49616

88-0488686

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego,
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement.

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement.

On August 4, 2006, Halozyme Therapeutics, Inc. (Halozyme) and Sorrento Square (Sorrento) entered into a First Amendment to Standard Industrial Lease (the First Amendment). The First Amendment is effective as of July 1, 2006 and it amends the Standard Industrial Net Lease Halozyme and Sorrento originally entered into on October 28, 2004 (the First Lease). On August 4, 2006, Halozyme and Sorrento also entered into a Second Amendment to Standard Industrial Lease (the Second Amendment and, along with the First Amendment, the Amendments). The Second Amendment is also effective as of July 1, 2006 and it further amends the Standard Industrial Net Lease Halozyme and Sorrento originally entered into on May 20, 2003 (the Second Lease and, along with the First Lease, the Leases).

Halozyme's primary administrative and research activities occur on the premises subject to the Leases, and the Amendments extend the terms of both Leases through December 31, 2007. In addition, the First Amendment increases Halozyme's administrative and research space through the addition of two extra suites. Halozyme will receive a tenant improvement allowance of \$83,500 under the First Amendment in connection with the addition of these two suites. The aggregate amount of minimum monthly rent that Halozyme owes to Sorrento under the Leases is also increased to approximately \$31,000 per month.

The preceding description of the Amendments is a summary of the material terms of those agreements and does not purport to be complete, and is qualified in its entirety by the copies of each such agreement which are attached to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
-------------	-------------

99.1	First Amendment to Standard Industrial Lease, effective as of July 1, 2006.
------	---

99.2	Second Amendment to Standard Industrial Lease, effective as of July 1, 2006.
------	--

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

August 8, 2006

By: /s/ David A. Ramsay

David A. Ramsay
Secretary and Chief Financial
Officer